Julie Kim
Tracked across 2 events · 27 articles · First seen Aug 05, 2026 · Last active Aug 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: As Takeda's president and CEO, Julie Kim celebrated the approval as a new chapter for the NT1 community and reaffirmed the company's commitment to bringing the drug to patients quickly.
Aug 05, 2026 · 21 articles
Regulatory
Impact: Takeda's CEO Julie Kim announced the approval, emphasizing the drug's first-in-class status and commitment to patients.
Aug 28, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Julie Kim live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard